New shot may ease itchy hives in teens
NCT ID NCT03437278
First seen Jan 17, 2026 · Last updated May 21, 2026 · Updated 25 times
Summary
This study tested a drug called ligelizumab in 49 teens aged 12 to 18 with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The goal was to see if adding ligelizumab to standard antihistamines could reduce itching and welts better than a placebo. Participants received injections and tracked their symptoms weekly. The trial was completed and focused on safety and symptom improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Rosario, Santa Fe Province, S2000BRH, Argentina
-
Novartis Investigative Site
Bahía Blanca, B8000JRB, Argentina
-
Novartis Investigative Site
Buenos Aires, C1125ABE, Argentina
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Montreal, Quebec, H3H 1P3, Canada
-
Novartis Investigative Site
Québec, Quebec, G1V 4W2, Canada
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Budapest, HUN, 1037, Hungary
-
Novartis Investigative Site
Nashik, Maharashtra, 422 101, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110 060, India
-
Novartis Investigative Site
Bikaner, Rajasthan, 334001, India
-
Novartis Investigative Site
Saint Petersburg, 191015, Russia
-
Novartis Investigative Site
Saint Petersburg, 191123, Russia
-
Novartis Investigative Site
Smolensk, 214019, Russia
-
Novartis Investigative Site
Barcelona, Barcelona, 08006, Spain
-
Novartis Investigative Site
Esplugues de Llobregat, Barcelona, 08950, Spain
-
Novartis Investigative Site
Taipei, Taiwan, 10002, Taiwan
-
Novartis Investigative Site
Aydin, Turkey, 09100, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, 06100, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.